Corteva stock presents a mixed valuation picture as the planned separations of Vylor and the future crop protection company approach. A Discounted Cash Flow model estimates an intrinsic value of about $111.87 per share, implying the stock is 23.3% undervalued relative to its current price. However, Corteva trades at 45.8 times earnings, well above the Chemicals industry average of 25.7 times and the model-implied fair multiple of 24.9 times, suggesting overvaluation on an earnings basis. The company has delivered a 108.5% total return over the past five years, and the upcoming spin-offs add execution risk that may weigh on investor sentiment.
Corteva IncDCF model suggests 23.3% undervaluation, but high P/E and execution risk from spin-offs create mixed signals.